Brief Articles Open Access
Copyright ©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Feb 28, 2009; 15(8): 942-954
Published online Feb 28, 2009. doi: 10.3748/wjg.15.942
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis
Eugen Florin Georgescu, Reanina Ionescu, Liliana Vancica, Department of Internal Medicine 2, Filantropia University Hospital, Str. Constantin Brancusi nr. 3, Craiova 200136, Romania
Eugen Florin Georgescu, Reanina Ionescu, Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Str.Petru Rares 4, Craiova 200349, Romania
Mihaela Niculescu, Laurentiu Mogoanta, Department of Pathology, University of Medicine and Pharmacy of Craiova, Str.Petru Rares 4, Craiova 200349, Romania
Mihaela Niculescu, Department of Pathology, Filantropia University Hospital, Str. Constantin Brancusi nr. 3, Craiova 200136, Romania
Author contributions: Georgescu EF conducted the trial, designed the study flowchart, analyzed the data and wrote the manuscript; Ionescu R participated in treating patients; Niculescu M performed the histology study; Mogoanta L supervised the histology database and the randomization procedure and analyzed data; Vancica L participated in treating patients, collecting the data and operating the database.
Correspondence to: Eugen Florin Georgescu, Professor, Department of Internal Medicine 2, Filantropia University Hospital, Str. Constantin Brancusi nr. 3, Craiova 200136, Romania.
Telephone: +40-374-011671  
Fax: +40-251-420896
Received: September 10, 2008
Revised: January 9, 2009
Accepted: January 16, 2009
Published online: February 28, 2009


AIM: To evaluate insulin resistance, cytolysis and non-alcoholic steatohepatitis (NASH) score (NAS) using the Kleiner and Brunt criteria in 54 patients with NASH and mild-to-moderate hypertension, treated with telmisartan vs valsartan for 20 mo.

METHODS: All patients met the NCEP-ATP III criteria for metabolic syndrome. Histology confirmed steatohepatitis, defined as a NAS greater than five up to 3 wk prior inclusion, using the current criteria. Patients with viral hepatitis, chronic alcohol intake, drug abuse or other significant immune or metabolic hepatic pathology were excluded. Subjects were randomly assigned either to the valsartan (V) group (standard dose 80 mg o.d., n = 26), or to the telmisartan (T) group (standard dose 20 mg o.d., n = 28). Treatment had to be taken daily at the same hour with no concomitant medication or alcohol consumption allowed. Neither the patient nor the medical staff was aware of treatment group allocation. Paired liver biopsies obtained at inclusion (visit 1) and end of treatment (EOT) were assessed by a single blinded pathologist, not aware of patient or treatment group. Blood pressure, BMI, ALT, AST, HOMA-IR, plasma triglycerides (TG) and total cholesterol (TC) were evaluated at inclusion and every 4 mo until EOT (visit 6).

RESULTS: At EOT we noticed a significant decrease in ALT levels vs inclusion in all patients and this decrease did not differ significantly in group T vs group V. HOMA-IR significantly decreased at EOT vs inclusion in all patients but in group T, the mean HOMA-IR decrease per month was higher than in group V. NAS significantly diminished at EOT in all patients with a higher decrease in group T vs group V.

CONCLUSION: Angiotensin receptor blockers seem to be efficient in hypertension-associated NASH. Telmisartan showed a higher efficacy regarding insulin resistance and histology, perhaps because of its specific PPAR-gamma ligand effect.

Key Words: Telmisartan, Valsartan, Non-alcoholic steatohepatitis, Hypertension, Insulin-resistance, Hepatic steatosis, Necroinflammation


Non-alcoholic fatty liver disease (NAFLD) is a condition pathogenically linked to the metabolic syndrome by the intervention of insulin resistance (IR), characterized by hepatic steatosis in the absence of significant alcohol use, hepatotoxic medications or other known liver disease[1]. Currently, NAFLD and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive chronic liver disease leading to cirrhosis and hepatocellular carcinoma[25]. All theories present NAFLD/NASH as the hepatic component of the metabolic syndrome (MS), whose central features include obesity, peripheral insulin resistance, diabetes, dislipidemia, and hypertension[68]. Potential therapies tested in NASH treat only the consequences of this condition or try to eliminate excessive fat and target the IR. Reducing food intake can limit accumulation of liver fat and can reverse IR, but there are no well-controlled trials for weight control as a therapy for NAFLD[9]. Other therapeutic interventions, pointing on other features of MS like dislipidemia and impaired glucose tolerance, trying to promote hepatic cytoprotection, or reduction of fibrosis were also evaluated.

This article focuses on angiotensin receptor blockers (ARB’s) as multivalent therapeutic agents for NASH, targeting not only hypertension, but also the mechanisms of IR and of hepatic injury via renin-angiotensin system (RAS) as prominent pathways of liver damage. The primary endpoints of the study were to prove that ARB’s can improve IR in mild-to-moderate hypertensive patients with histologically confirmed NASH, and that monotherapy with ARBs, on regularly basis, can ameliorate cytolysis, while biochemical improvement in these patients correlates with amelioration of NASH activity score. The secondary endpoint was to prove certain superiority of telmisartan vs valsartan in NASH-hypertensive patients regarding IR, cytolysis, and necroinflammation, given its specific PPAR-γ modulatory effects.

Study population and screening

The study conducted between May, 2006 and November, 2007 at Filantropia University Hospital from Craiova-Romania was in accordance with the Helsinki Declaration of 1975, and approved by the Review Ethics Board of the University Medicine and Pharmacy of Craiova and of the Filantropia University Hospital. We screened for MS in 294 patients, using the definition accepted in the 2001 guidelines by the National Cholesterol Education Project Adult Treatment Panel (NCEP-ATP III)[10]. Only 159 of 294 patients (54.1%) met the NCEP-ATP III criteria (P = 0.179, χ2 = 1.79) and only 89 of the 159 subjects had mild-to-moderate hypertension (57.8%, P = 0.153, χ2 = 2.03).

Patients had to give full informed consent, including paired liver biopsies, and to be between 18 and 65 years old. The inclusion criteria also included confirmation of MS by NCE-ATP III criteria, in subjects with mild-to-moderate hypertension documented by Holter evaluation up to 4 wk prior inclusion, with systolic BP between 180 mmHg and 135 mmHg and the diastolic between 120 mmHg and 85 mmHg and having ALT values more than 1.5-fold normal range (30 IU/dL maximum normality) for at least at 2 determinations, up to 4 weeks prior inclusion. All patients had to have a fasting plasma glucose (FPG) level less than 130 mg/dL, without any therapy or low-carbohydrate diet for at least three determinations up to two weeks prior inclusion, and histologically[11] confirmed NASH with a necroinflammatory score of 5 or more up to 3 wk before inclusion (according to the scoring system proposed and validated for use in clinical trials by the Pathology Committee of the NASH Clinical Research Network in 2005; available at Other inclusion criteria included acceptance of alcohol abstinence, acceptance of taking the study medication daily at the same hour, and answering at each visit an alcohol consumption questionnaire for monitoring alcohol intake, adapted from Behavioral Risk Factor Surveillance System[12] 2007 Questionnaire (available at Little amounts of alcohol were allowed occasionally, but not more than two drinks/week (one standard US alcoholic drinks = 14 g pure alcohol). No dietary restrictions or lifestyle modifications were imposed in any case, except current recommendations made by the general practitioner at the regular visits, and no concomitant medication was allowed 1 mo before and after treatment as well as for the entire period of study.

Uncontrolled hypertension or requiring more than a single drug to obtain BP control, history of or confirmed viral hepatitis at screening, drug or alcohol abuse and any other concomitant/pre-existing metabolic or immune hepatic disease were exclusion criteria, as well as normal ALT, HIV positivity and use of dietary supplements, or any other concomitant medication taken on a regularly basis. Dramatic lifestyle changes (e.g. low-calorie diets, intensive physical training, surgery for obesity) were not permitted during the study and patients were encouraged to keep their regular dietary habits and to avoid weight variations. Patients unable to give informed consent, refusing paired liver biopsies, or having any other severe associated organic or psychiatric pathology, neoplasia, or history of intolerance to ARBs were also excluded.

By checking the inclusion/exclusion criteria, only 72/89 patients continued the screening and underwent liver biopsy. The study design scheduled two liver biopsies: the first biopsy performed up to 3 wk prior inclusion (considered as the index biopsy) and the second biopsy obtained at maximum 2 wk after the end of treatment. A single pathologist, unaware of patient information, evaluated the histological features of both index and second biopsies. NAFLD activity scores (NAS) were assessed in each case, and patients with simple steatosis, or those not fully meeting all criteria for steatohepatitis (18/72), were excluded. We finally included 54 subjects (28M/26F) in the trial.

Subjects were randomly assigned using dedicated computer software either to the valsartan (V) group (receiving a standard dose of 80 mg o.d., n = 26), or to the telmisartan (T) group (standard dose 20 mg o.d., n = 28). Medication was blinded and treatment had to be taken daily at the same hour in the morning, with no concomitant medication or alcohol consumption allowed. Neither the patient nor the medical staff was aware of the treatment group allocation.

Biochemical analyses and histology

A central laboratory used standard procedures to insure reproducibility. FPG, alanine-aminotransferase (ALT), aspartate-aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), bilirubin (B), total cholesterol (TC), and triglycerides (TG), were determined on fresh serum using an autoanalyzer Hitachi 917 Automate with Roche Diagnostics reagents. Serum samples obtained after an overnight fast of at least 12 h and immediately frozen at -20°C were used to determine the levels of immunoreactive insulin (IRI) by a chemiluminescence immunoassay (Elecsys Modular Analytics E170; Roche Diagnostics) using monoclonal antibodies with stated negligible cross-reactivity. We determined IR by the homeostasis model assessment (HOMA-IR) method[13] using the following equation: HOMA-IR = [FPG (mg/dL) × IRI (&mgr;U/mL)]/405.

The percutaneous liver biopsy technique was performed in all cases[14]. All biopsies were fixed, paraffin-embedded, and stained with hematoxylin-eosin and Masson’s trichrome/picrosirius red for collagen. Biopsies were evaluated by a single, experienced, blinded pathologist, not aware about allocation in one or another treatment group and about the clinical and biochemical parameters of any patient using the scoring system validated by Kleiner et al[11]. As known, this histology scoring system quantifies necroinflammatory and steatotic changes (steatosis, lobular inflammation, and ballooning) resulting NAFLD activity scores (NAS) that range between 0 and 8. Scores greater or equal to 5 are largely diagnostic for NASH, while scores less than 4 characterize a fatty liver having simple steatosis, but not NASH. Fibrotic changes are evaluated separately from NAS, ranging from 0 (no fibrosis) to 4 (cirrhosis). Our study also assessed the fibrosis stage in all patients in order to evaluate the antifibrotic effects of the two ARBs.

Study schedule and surveillance parameters

After screening, the included patients were followed for 20 mo. The study flowchart previewed 6 visits (V1-V6) scheduled every 4 mo (112 d) with a ± 5 d deviation admitted. Each visit took place between 8.00 and 11.00 a.m. and consisted with a clinical examination, blood pressure (BP) and body mass index (BMI) determinations, serum sampling, and a questionnaire. An average of three successive determinations of systolic (sBP) and diastolic (dBP) BP was calculated and used in records each visit. BMI was computed using the formula: [weight (kg)]/[square of height (meters)], while serum was collected for FPG, ALT, AST, GGT, B, TC, TG and IRI determinations. An alcohol consumption questionnaire was also administered each visit and study compliance was strictly monitored, including checking the returned medication. Additionally, V1 (inclusion) comprised recording of the result of the index liver biopsy which was performed -21 to -7 d previously, while V6 ended with the second liver biopsy, performed at maximum 2 wk after the end-of treatment (EOT).

The primary parameters at followed-up were s/dBP, BMI, ALT, AST, GGT, HOMA-IR, TC, TG, NAS and fibrosis scores. Additionally, we used in the analysis the following derivate parameters: the mean monthly decreases of ALT (mMd*ALT), HOMA-IR (mMd*HOMA-IR), TC (mMd*TC) and TG (mMd*TG), the mean decrease for NAS (md*NAS) and fibrosis score (md*Fibrosis) and the mean decrease of s/dBP (md*s/dBP) and BMI (md*BMI). The mMd*ALT, mMd*HOMA-IR, mMd*TC and mMd*TG represent the difference between the average values of respectively, ALT, HOMA-IR, TC and TG, between V2 and V6 and their mean values at V1 divided by the number of months of follow-up (20 mo for the patients that fully completed treatment), mathematically expressed by the following formula (where “y” is the study parameter, “i” is the number of the visit, “Ni is the number of months of follow-up and “Vi is the index of the visit).

The md*NAS and md*Fibrosis were calculated by subtracting the average NAS and, respectively, fibrosis scores at index biopsy from those recorded at V6, while the md*s/dBP and md*BMI represent the difference between the respective values of these parameters averaged from V2 to the last visit and their mean value at V1 without considering the number of months of follow-up, as in the subsequent formula (where “z” is the study parameter, “i” is the number of the visit, and “Vi is the index of the visit):

Statistical analysis

Data is presented as mean ± SE. Differences in the baseline parameters between groups T and V were tested by the Kruskal-Wallis test to check for any baseline bias. Normal distribution was tested using the Kolmogorov-Smirnov test while the Wilcoxon test was used to assess the differences between the paired observations. Other data recorded during the study from groups T and V were analyzed by one-way analysis of variance ANOVA. A statistically significant result was considered when P value was less than 0.05. All statistical analyses were performed using the MedCalc Software Version (MedCalc Software, Broekstraat 52, 9030 Mariakerke, Belgium).


Mean age for the included patients was 48.89 ± 1.41 (48 ± 1.98 in group T and 49.85 ± 2.05 in group V) while the average dose per BMI unit was 0.74 ± 0.01 mg telmisartan in group T and 2.92 ± 0.06 mg valsartan in group V. No statistically significant difference between the two groups regarding the demographic data, as well as among the survey parameters, existed at inclusion. Table 1 shows a synopsis of all the survey parameters at baseline in all included patients, as well as in the two therapeutic groups.

Table 1 Demographics and baseline data at inclusion (mean  ±  SE).
UnitsOverall patientsGroup
No. of patients542826NS
Ageyr48.89 ± 1.4148 ± 1.9849.85 ± 2.05
BMI (V1)kg/m227.42 ± 0.3627.21 ± 0.5127.65 ± 0.53NS
dBP (V1)mmHg101.65 ± 1.05101.43 ± 1.17101.89 ± 1.8
sBP (V1)mmHg156.53 ± 1.28155.71 ± 1.61157.42 ± 2.04
ALT (V1)IU/L67.65 ± 2.0166.96 ± 2.9568.38 ± 2.75NS
AST (V1)IU/L70.31 ± 2.3472.78 ± 3.5367.65 ± 3.02
GGT (V1)IU/L23.85 ± 1.6222.60 ± 2.3725.19 ± 2.22
B (V1)mg/dL0.89 ± 0.020.9 ± 0.030.88 ± 0.04
HOMA IR (V1)units7.7 ± 0.247.81 ± 0.407.58 ± 0.25
IRI (V1)&mgr;U/mL27.64 ± 0.8627.78 ± 1.1427.50 ± 1.32
FPG (V1)mg/dL113.83 ± 1.98113.60 ± 2.77114.07 ± 2.88
HDL-C (V1)mg/dL42.44 ± 1.242.34 ± 1.6842.54 ± 1.77NS1
M: 37.8 ± 1.38M: 37.45 ± 1.86M: 38.16 ± 2.11
F: 47.42 ± 1.5F: 47.23 ± 2.13F: 47.66 ± 2.19
TC (V1)mg/dL196.46 ± 1.13196.07 ± 1.5196.88 ± 1.73NS1
M: 200.82 ± 1.2M: 200.57 ± 1.29M: 201.07 ± 2.07
F: 191.77 ± 1.5F: 191.57 ± 2.13F: 192 ± 2.19
TG (V1)mg/dL161.51 ± 4.91165.64 ± 6.95157.08 ± 7.18
NAS (V1)points5.89 ± 0.146 ± 0.185.77 ± 0.22NS
Steatosis (V1)2.16 ± 0.092.21 ± 0.122.11 ± 0.16
Lobular inflammation (V1)1.70 ± 0.061.68 ± 0.091.73 ± 0.09
Ballooning (V1)2.02 ± 0.12.11 ± 0.131.92 ± 0.16
Fibrosis (V1)points2.11 ± 0.112.07 ± 0.162.15 ± 0.15NS

All included patients finished the study. At the end of the study, we observed significant differences regarding biochemical, metabolic, histological and hemodynamic parameters in both study groups compared with inclusion data. Tables 2 and 3 review the main results of the study concerning both the primary parameters of survey as well as the derivate ones.

Table 2 Comparative overview of the primary parameters at inclusion versus end-of-treatment in study groups and in overall patients.
Group T
Group V
mean ± SEPmean ± SEPmean ± SEP
sBP (V1)mmHg156.54 ± 1.28< 0.0001155.71 ± 1.61< 0.0001157.42 ± 2.04< 0.0001
sBP (V6)134.24 ± 1.28133.21 ± 1.23135.35 ± 2.31
dBP (V1)mmHg101.65 ± 1.05< 0.0001101.43 ± 1.17< 0.0001101.89 ± 1.8< 0.0001
dBP (V6)77.8 ± 1.0477.14 ± 1.2578.5 ± 1.7
ALT (V1)IU/L67.65 ± 2.01< 0.00166.96 ± 2.95< 0.00168.38 ± 2.75< 0.001
ALT (V6)49.48 ± 1.1646.68 ± 1.4252.50 ± 1.70
AST (V1)IU/L70.31 ± 2.34< 0.00172.78 ± 3.53< 0.00167.65 ± 3.02< 0.001
AST (V6)51.11 ± 1.8347.57 ± 2.0854.92 ± 2.95
GGT (V1)IU/L23.85 ± 1.62NS22.60 ± 2.37NS25.19 ± 2.22NS
GGT (V6)21.02 ± 1.9821.96 ± 3.5520 ± 1.58
B (V1)mg/dL0.89 ± 0.02NS0.9 ± 0.03NS0.88 ± 0.04NS
B (V6)0.94 ± 0.020.94 ± 0.030.93 ± 0.03
BMI (V1)kg/m227.42 ± 0.36NS27.21 ± 0.51NS27.65 ± 0.53NS
BMI (V6)26.96 ± 0.3626.93 ± 0.4927.00 ± 0.54
HOMA-IR (V1)mg ×&mgr;IU7.7 ± 0.24< 0.0017.81 ± 0.40< 0.0017.57 ± 0.25< 0.05
HOMA-IR (V6)/dL × 10-25.19 ± 0.184.48 ± 0.215.95 ± 0.22
TG (V1)mg/dL161.51 ± 4.98< 0.051165.64 ± 6.95< 0.0311157.08 ± 7.18NS1
F: 168.42 ± 8.28F: 169.85 ± 11.2F: 166.75 ± 12.82
M: 155.10 ± 5.63M:161.42 ± 8.49M: 148.78 ± 7.31
TG (V6)153.96 ± 4.8154.14 ± 6.79153.77 ± 6.93
F: 160 ± 8.29F: 156.78 ± 11.33F: 163.75 ± 12.61
M: 148.35 ± 5.09M: 151.5 ± 7.88M: 145.21 ± 6.65
TC (V1)mg/dL196.46 ± 1.13< 0.0081196.07 ± 1.5< 0.0241196.88 ± 1.73NS1
F: 191.77 ± 1.5M: 200.57 ± 1.29M: 201.07 ± 2.07
M: 200.82 ± 1.2F: 191.57 ± 2.13F: 192 ± 2.19
TC (V6)194.04 ± 1.19191.89 ± 1.64196.35 ± 1.64
F: 189.73 ± 1.58F: 188 ± 2.23F: 191.75 ± 2.19
M: 198.04 ± 1.39M: 195.79 ± 1.96M: 200.29 ± 1.87
NAS (V1)Point5.89 ± 0.14< 0.00116 ± 0.18< 0.04515.77 ± 0.22NS1
Steatosis2.16 ± 0.092Excepting inflammation (V1) vs (V6)2.21 ± 0.122.11 ± 0.162Excepting steatosis (V1) vs (V6) P = 0.027
Inflammation1.70 ± 0.06NS1.68 ± 0.091.73 ± 0.09
Balooning2.02 ± 0.12.11 ± 0.131.92 ± 0.16
NAS (V6)4.96 ± 0.144.57 ± 0.185.38 ± 0.2
Steatosis1.74 ± 0.091.71 ± 0.111.77 ± 0.15
Inflammation1.55 ± 0.101.32 ± 0.121.81 ± 0.14
Balooning1.67 ± 0.081.53 ± 0.111.81 ± 0.13
Fibrosis (V1)Point2.11 ± 0.11< 0.0012.07 ± 0.16< 0.0012.15 ± 0.15NS
Fibrosis (V6)1.57 ± 0.091.32 ± 0.131.84 ± 0.11
Table 3 Derivate study parameters in treatment groups and in overall patients (mean  ±  SE).
UnitsOverallGroup TGroup V
mMd*ALTIU/dL per month-0.57 ± 0.05-0.63 ± 0.09-0.52 ± 0.05
mMd*HOMA-IRunits/mo-9.63 ± 0.94 × 10-2-13.7 ± 1.32 × 10-2-5.3 ± 0.64 × 10-2
mMd*TGmg/dL per month-1.79 ± 0.10-1.99 ± 0.16-1.58 ± 0.11
mMd*TCmg/dL per month-0.03 ± 0.03-0.12 ± 0.05  0.06 ± 0.02
md*BMIunits  0.03 ± 0.36  0.11 ± 0.47-0.05 ± 0.57
md*sBPmmHg-21.13 ± 1.13-21.35 ± 1.68-20.90 ± 1.54
md*dBPmmHg-19.18 ± 1.43-19.65 ± 2.15-18.67 ± 1.91
md*NASpoint-0.92 ± 0.14-1.43 ± 0.19-0.38 ± 0.17
md*Fibrosispoint-0.46 ± 0.11-0.75 ± 0.13-0.15 ± 0.18
Cytolysis study

ALT values at V6 were significantly lower versus inclusion in all patients (49.48 ± 1.16 IU/L vs 67.65 ± 2.01 IU/L, P < 0.001), although the values did not returned to normality in either group. Both therapeutic groups had significantly lower ALT levels at EOT compared to V1; however, in group T these values were significantly smaller than in group V (46.68 ± 1.42 IU/L vs 52.50 ± 1.70 IU/L, P = 0.011). Despite a constant decrease of ALT in both groups from V2 to V6 with differences in favor of group T (Figure 1A), significantly lower values in this group, as compared to group V, were observed only at the last visit. As Table 2 shows, similar data with significantly lower values in group T vs V (47.57 ± 2.08 vs 52.50 ± 1.70, P = 0.044) were noticed for AST, but not for GGT and B which remained stable in both groups throughout the study.

Figure 1
Figure 1 Primary parameters of the biochemical study. Comparative dynamics for ALT and HOMA-IR from V1 to V6 in the study groups. A: ALT variation from V1 to V6; B: HOMA-IR variation from V1 to V6. ALT: Alanine-aminotransferase; HOMA-IR: Homeostasis model assessment index for insulin-resistance; V1 to V6: Number of scheduled visit; T: Telmisartan study group; V: Valsartan study group; NS: Not statistically significant.

The overall mMd*ALT value was -0.57 ± 0.05 IU/L per month, with -0.63 ± 0.09 IU/L/mo in group T and -0.52 ± 0.05 in group V (Figure 2A). No significant difference between groups regarding this aspect was observed either.

Figure 2
Figure 2 Derivate parameters of the biochemical study. Comparisons (box-and whisker means) of the averaged decreases per month for ALT, HOMA-IR, TC and TG in the two study groups. A: Mean monthly decrease for ALT; B: Mean monthly decrease of HOMA-IR; C: Mean monthly decrease of triglycerides;
Metabolic study

BMI was stable during the study in all patients (27.42 ± 0.36 vs 26.96 ± 0.36, P = NS) with no difference between group T and V at V6 (26.93 ± 0.49 in group T vs 27.00 ± 0.54, P = NS) and no differences were found between the two groups regarding the md*BMI (0.11 ± 0.47 in group T vs -0.05 ± 0.57 in group V, P = NS). At EOT, HOMA-IR was 5.19 ± 0.18, significantly lower than 7.7 ± 0.24 as found at V1 in overall patients (P < 0.001). Although this parameter significantly decreased in both groups compared to inclusion demonstrating an amelioration of insulin-sensitivity by both ARBs (P < 0.01), in group T this improvement was more important than in group V with P < 0.001 when comparing the HOMA-IR (V6) values between group T and V (4.48 ± 0.21 vs 5.95 ± 0.22). As shown in Figure 1B, the HOMA-IR constantly decreased in both groups, with significantly lower values for group T vs V from V2 to V6, proving a better insulin-sensitizing activity for telmisartan. Moreover, the mMd*HOMA-IR, which was -9.63 ± 0.94 × 10-2 units/mo in overall patients, was more than two-fold higher in group T with -13.7 ± 1.32 × 10-2vs -5.3 ± 0.64 × 10-2 units/mo in group V (P = 0.001), demonstrating a reliable effect of telmisartan to improve insulin resistance (Figure 2B).

Lipid profiles were also modified at the EOT. We noticed a decrease of TG values in patients at V6 compared to V1 (153.96 ± 4.8 mg/dL vs 161.51 ± 4.98 mg/dL, P = 0.003) in both in male and female patients, as shown in Table 2. However, only in group T was the decrease of plasma TG found to be statistically significant by the Wilcoxon test for paired samples (154.14 mg/dL ± 6.79 vs 165.64 ± 6.95 mg/dL, P = 0.0013). Moreover, although the mean values for TG were similar in groups T and V at V6, the mMd*TG was significantly higher in the telmisartan group, with -1.99 ± 0.16 mg/dL per month vs -1.58 ± 0.11 in group V (P = 0.043), irrespective of gender of patients (Figure 2C). TC decreased at V6 compared to V1 both in men (198.04 ± 1.39 mg/dL vs 200.82 ± 1.2 mg/dL, P = 0.006) as in women (189.73 ± 1.58 mg/dL vs 191.77 ± 1.5 mg/dL, P = 0.008) and in overall patients (194.04 ± 1.19 mg/dL vs 196.46 ± 1.13 mg/dL, P = 0.003). We did not noticed any difference regarding these values at V6 between groups T and V, when analyzing the results either by gender or in overall patients (191.89 ± 1.64 mg/dL vs 196.35 ± 1.64 mg/dL, P = 0.06). However, at EOT group T had significant lower values compared with inclusion in both male (195.79 ± 1.96 mg/dL vs 200.57 ± 1.3 mg/dL, P = 0.024) and female patients (188 ± 2.23 mg/dL vs 191.57 ± 2.13 mg/dL, P = 0.006) while in group V we did not observed the same aspect. Furthermore, as showed in Figure 2D, the mMd*TC was higher in group T than in group V (-0.12 ± 0.05 mg/dL vs -0.06 ± 0.02 mg/dL per month, P = 0.003) demonstrating a significant effect on the lipid profile by telmisartan, whereas valsartan seemed to lack this property.

Histology study

NAS score decreased at EOT in overall patients (5.89 ± 0.14 vs 4.96 ± 0.14, P < 0.01), but only steatosis and ballooning showed a significant reduction, while lobular inflammation rested unchanged. The NAS score at V6 was lower in group T vs V (4.57 ± 0.18 vs 5.38 ± 0.2, P = 0.004) demonstrating a significant efficacy of telmisartan to improve hepatic histology. Additionally, when comparing the evolution of the NAS elements in the two groups, we found that all these components significantly decreased in group T from V1 to V6 (P < 0.045 for any comparison V1 vs V6 concerning steatosis, lobular inflammation and ballooning), while in group V, only steatosis improved (P = 0.027) without significant changes for inflammation and ballooning (Figure 3A). Furthermore, the md*NAS was significantly higher in telmisartan group (-1.43 ± 0.19 vs -0.38 ± 0.17, P < 0.001) confirming that this ARB can effectively act as a factor promoting amelioration of the NASH activity score (Figure 3B).

Figure 3
Figure 3 Histology study. Comparisons of averaged decreases for NAS and its components and for the fibrosis scores between V1 and V6 among the study groups. A: Comparison between the values of NAS components at V6 vs V1; B: Mean NAS decrease in groups T and V; C: Comparison between the values of NAS and respectively fibrosis scores at V6 vs V1; D: Mean decrease of fibrosis scores in groups T and V. St: Steatosis; LI: Lobular inflammation; B: Ballooning; NAS: NASH activity score; V1: Index data at visit 1; V6: End-of-treatment data; NS: Not statistically significant.

In all groups, the fibrosis scores at V6 were lower than those observed at V1 (1.57 ± 0.09 vs 2.11 ± 0.11, P < 0.001); however, fibrosis scores at EOT were higher in group V than in group T (1.84 ± 0.11 vs 1.32 ± 0.13, P = 0.013). The decrease of the fibrosis score from V1 to V6 was statistically significant in group T (2.07 ± 0.16 to 1.32 ± 0.13, P < 0.001), but not in group V, demonstrating an antifibrotic effect of telmisartan that is not possessed by the other ARB (Figure 3C). Moreover, the md*Fibrosis was significantly higher in group T than in group V (-0.75 ± 0.13 vs -0.15 ± 0.18, P = 0.01), confirming the capacity of telmisartan to inhibit liver fibrosis (Figure 3D).

Hemodynamic study

A detailed analysis of the antihypertensive effect of the two ARBs was not the scope of this study. We only noticed that both drugs are equally potent in reducing both sBP and dBP. Telmisartan reduced BP from 155.71 ± 1.61/101.43 ± 1.17 mmHg at V1 to 133.21 ± 1.23/77.14 ± 1.25 mmHg at V6, while valsartan reduced BP from 157.42 ± 2.04/101.89 ± 1.8 at V1 to 135.35 ± 2.31/78.5 ± 1.7 at V6. No differences were noticed between groups regarding either sBP or dBP at any of the visits from V2 to V6, while the md*sBP and md*dBP values were, respectively, -21.35 ± 1.68 mmHg in group T vs -20.90 ± 1.54 in group V and -19.65 ± 2.15 mmHg in group T vs -18.67 ± 1.91 in group V (P = NS for both comparisons).


In brief, our study demonstrates that although it does not normalize ALT values, telmisartan can reduce cytolysis by 30.28% and can improve IR by decreasing HOMA-IR with 42.63% in patients with NASH and mild-to-moderate hypertension. This improvement is associated with a significant decrease of NAS and fibrosis scores and with an amelioration of the lipid profile demonstrated by lower values of plasma TG and TC in both men and women. On the other hand, despite a significant reduction of ALT levels by 23.22% and of HOMA-IR by 21.4%, valsartan did not improve liver histology (except steatosis) and had no effect on plasma lipids. There is no statistically significant difference in ALT reduction between the two ARBs, but the higher rates of HOMA-IR reduction, as well as the improvement of NAS score and antifibrotic effect observed in group T, suggests that the effects of this ARB are driven not only through the angiotensin-1 receptor blockade, but also via its PPAR-γ modulator specific effects.

Telmisartan is an ARB possessing unique qualities of PPAR-γ modulation that makes it ideal for the treatment of NASH. Unfortunately, no major studies have been performed to confirm its efficacy in steatohepatitis, although a theoretical and experimental fundament exists[15]. Interestingly, a study by Fujita et al[16] tested the same compounds as we did in this study in a rat model of NASH, providing evidence that telmisartan, but not valsartan, improved both qualitatively and quantitatively hepatic steatosis, inflammation, and fibrosis. Furthermore, in both rats with choline-deficient diet-induced NASH (in vivo) and in primary hepatic stellate cells (in vitro), Jin et al[17] concluded that telmisartan is able to prevent liver fibrosis by increasing matrix-metaloproteinase (MMP) expression, down-regulation of transforming growth factor beta-1 (TGF-β1) and tissue inhibitor of matrix-metalloproteinases (TIMP), and by inhibition of hepatic stellate cell (HSC) activation and proliferation. A study by Sugimoto et al[18] provides evidence that in hepatic steatosis telmisartan (and not valsartan) reduces accumulation of visceral fat and hepatic triglyceride levels, decreases adipocyte size, and increases the muscle expression of certain important genes involved with energy metabolism. These properties of telmisartan are probably linked to its ability to modulate PPARγ activity. Indeed, in a recent study, Yoshida et al[19] demonstrated that telmisartan improves IR in advanced glycation end-product (AGE)-exposed human hepatoma (Hep3B) cells by decreasing serine phosphorylation and enhancing tyrosine phosphorylation of insulin-receptor substrate-1 but, when antagonized with an inhibitor of PPARγ, it loses these properties. Other animal studies[2023] provided additional evidence of properties of telmisartan linking it to PPAR modulation that can account for its effects in steatohepatitis, for example a partial PPAR-α agonist activity which seems to be restricted to the liver, regulating serum adipokines with increased adiponectin and decreased resistin levels, and even anti-inflammatory properties.

Human studies employing ARBs in NASH are quite rare[2426], testing habitually losartan and lacking either a sufficient number of patients, either an adequate assessment of morphologic changes given the difficulty to obtain paired liver biopsies. The major strength of our study is that, from our knowledge, it is the first human blinded trial evaluating the effects of telmisartan and valsartan in steatohepatitis that uses paired liver biopsies simultaneously with cytolysis and IR assessment. Interestingly, although not pointing on steatohepatitis, a recent study by Ichikawa[27] demonstrated that in hypertensive patients with MS, receiving 20 mg telmisartan daily for 4 wk, resulted in a reduction of HOMA-R by 16%, while 40 mg valsartan/day did not show significant results on this parameter. There are differences between this study and our trial, including different dosage for valsartan (higher doses in our study), longer period of survey (20 mo vs 4 mo), younger study population (49 years vs 65 years), higher values of HOMA-IR (7.7 units vs 3 units), use of Japanese criteria for MS and permission for concomitant medication, but in all, our results confirm the insulin-sensitizing effect of telmisartan. Additionally, we demonstrated that this ARB has a favorable effect on plasma TG and TC in opposition to Ichikawa and other groups[2829], but in accordance with others[3034]. As for valsartan, again in contrast with Ichikawa, but in accordance with larger studies[3536], we demonstrated that it also reduces IR, although it has no other effects on lipid profiles.

There are interesting theories and experimental facts that can explain the intervention of the RAS in liver disease, leading to the theoretical conclusion that ARBs have the capacity to become the first-class option for a tailored therapy in NAFLD and NASH. The RAS is an enzymatic cascade in which renin, an aspartic protease released from juxtaglomerular cells, cleaves angiotensinogen to form a decapeptide, angiotensinI(Ang-I), which is in turn transformed to angiotensin II (Ang-II) by the angiotensin-converting enzyme (ACE). Ang-II can be further converted by aminopeptidases A and N in Ang-III (2-8) which is finally transformed in Ang-IV (3-8)[37]. Historically, Ang-II was first described as the primary effector of this system, but more recent research added new components as a result of the action of prolylendopeptidase and carboxypeptidases: angiotensin 1-5 (Ang-1-5), angiotensin 1-7 (Ang-1-7), and angiotensin 1-9 (Ang-1-9)[38]. Ang-1-7 is a heptapeptide generated from either Ang-Ior Ang-II by a homologue of ACE, angiotensin converting enzyme 2 (ACE2) which has a catalytic domain different from ACE and acts antagonistically as a counter-regulatory factor. The biological actions of Ang-1-7 are both activation of peripheral vasodilatory mechanisms and antitrophic effects mediated by the inhibition of protein synthesis[3940].

Classically, Ang-II and Ang-III acts on two types of G-protein-coupled receptors, AT1 and AT2. The AT1 receptor is widely expressed in various tissues (heart, kidney, vessels, liver and adipocytes), while AT2 has low levels of expression after birth, but may play a role in activation of AT1, modulation of cell differentiation, tissue repair and apoptosis[41]. Ang-IV possesses its own receptors (AT4) distinct from AT1 and 2, and Ang-1-7 acts through a different G protein-coupled receptor (Mas) downregulating AT1[42].

Although consistent convergent data about the intervention of the RAS in NAFLD/NASH exists, the contribution of this factor in setting and promoting the hepatic consequences of MS is still not fully clarified. It is likely that the mechanisms by which RAS could interfere with the pathogenic course that links IR to steatohepatitis might include interactions with insulin receptors and intracellular signalling, effects on adipogenesis, influences on cytokine and adipokine production, interferences with pancreatic β-cell insulin secretion and/or local hepatic effects interfering hepatocellular regulatory mechanisms.

Angiotensinogen is synthesized in the liver and adipocytes, but adipose tissue differs from liver given the differences in the AT1/AT2 receptor populations, the inhibitory effect of the AT2 receptors impairing excessive angiotensinogen production by the adipocytes[43]. RAS is frequently activated in the patients with chronic liver diseases, promoting mainly fibrosis, with Ang-II stimulating contractility and proliferation of the activated HSCs, increasing TGF-β1 and promoting neovascularization and production of vascular endothelial growth factor[44]. It is largely accepted[45] that the local hepatic RAS system acts almost exclusively through the AT1 receptors localized to hepatocytes, bile duct epithelial cells, HSCs, myofibroblasts, Kupffer cells and vascular endothelium, as the AT2 receptors are not significantly expressed in liver. However, some data regarding the AT2 receptors exists suggesting that it may have protective effects against fibrosis[46].

Although the profibrotic effects of RAS begins to be unveil in various conditions including NASH, little is known about the inflammatory changes that precede fibrosis. Perfusion studies by Bataller and colleagues showed mild portal inflammation, thickening and thrombosis of small hepatic vessels, as well as accumulation of CD43-positive inflammatory cells and activated HSCs in pericentral areas following infusion of Ang-II, and concluded that liver injury is induced in this circumstance by oxidative stress, hepatic inflammation, and vascular damage[47]. It is considered[48] that Ang-II acts by amplifying the general inflammatory response that follows the chronic liver injury, inducing reactive oxygen species (ROS) generation as well as inflammatory cytokines like interleukins (IL) -6 and -1, monocyte chemoattractant protein-1 (MCP-1), TGF-β1 and tumor necrosis factor-α (TNF-α). More complex connections and interferences are, however, occurring in real conditions, like the crosstalk between TNF-α and RAS in the TNF-induced plasminogen activator inhibitor-1 (PAI-1) production in human hepatocytes[49]. Accordingly, gene expression of RAS and that of PAI-1 are upregulated in the liver of patients with obesity and type 2 diabetes, and in non-malignant human hepatocyte cell lines, RAS-encoding genes are upregulated time-dependently by TNF-α while AT1-receptor blockade inhibits the TNF-induced PAI-1 production.

The mechanisms of inflammatory activation induced by Ang-II are classic. AT1 receptor binding, with subsequent protein kinase C (PKC) activation followed by the intervention of intracellular signalling systems, like extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK). c-Jun leads to the activation of nuclear factor-κB (NF-κB), preceded by the release of several of transcription factors, like activator protein-1 (AP-1) and signal transducer and activator of transcription (STAT), the final result being transcription and delivery of proinflammatory cytokines[50]. Additionally, other NF-κB-dependent inflammatory proteins such as cyclooxygenase-2 (COX2) and inducible nitric oxide synthase (iNOS) are upregulated by angiotensin. Jamaluddin et al[51] recently described in liver cells an alternate pathway for NF-κB activation similar to the signalling pathway that mediates antigen-induced lymphocyte proliferation by bridging T or B cell receptor. It can be, therefore, speculated that such a pathway can account for inflammatory changes that occur when “simple steatosis” turns to “steatohepatitis”. Moreover, as activation of NF-κB is also followed by further stimulation of angiotensinogen transcription in hepatocytes by Ang-II via the AT1 receptors[52], thus inducing expression of its own precursor and creating a biological “positive feedback loop”, it is possible that this pathway represents one of the key factors that contributes to the vicious cycle of liver damage.

The key factors in promoting hepatic fibrosis are the HSCs, together with the portal myofibroblasts and cells of bone marrow origin which exhibit fibrogenic potential[53]. In liver fibrosis, the resident HSCs appears to be the primary source of myofibroblasts, although bone-marrow-derived cells can also contribute[54]. Chemokines attracting mononuclear phagocytes like MIP-1α (CCL3) and MCP-1 (CCL2) are considered as main profibrotic mediators, while TGF-β1 and Th2 cytokines (IL-4, IL-5, IL-13 and IL-21) have distinct roles in the regulation of tissue remodelling and fibrosis[55]. TGF-β1 is the best known pro-fibrotic cytokine, being stored in macrophages as an inactive homodimer that needs to be dissociated by several enzymes, like cathepsin, plasmin, integrins and MMPs, to bind to the specific receptors and to trigger intracellular intermediates (SMAD proteins) which induce procollagenIand III synthesis[56].

HSCs are the main source of extracellular matrix (ECM) in liver, residing in the space of Disse. When activated, HSCs express contractile, proinflammatory, and fibrogenic factors, migrate, secrete ECM, and regulate ECM degradation[57] by expressing MMPs. Activated HSCs are also a major source for additional proinflammatory mediators and cytokines and are able to de novo generate Ang-II[58], being the key factor to maintain the vicious cycle which links inflammation to fibrosis. There is a consensus that Ang-II and local RAS are major pro-fibrotic agents in liver, inducing all the pro-fibrogenic properties of HSCs. Consequently, there are multiple points in which Ang-II, acting on the AT1 receptors, increases the ability of HSCs to generate fibrosis, including stimulation of chemoatractant factors, activation of contractile and secretory properties of HSCs and imbalance of the production and removal of ECM.

Further, with the stimulatory effects of Ang-II on MCP-1 and TGF-β1, with the implication of the AT1 receptor-mediated NF-κB-dependent pathway in this phenomenon, and its effects on TGF-β1 secretion and activation, Ang-II also enhances HSC’s intracellular signalling by increasing SMAD levels and the nuclear translocation of phosphorylated SMAD with subsequent production of collagens, fibronectin and proteoglycans[59]. The contractile functions of activated HSCs, derived from intracellular smooth muscle actin expression, are also stimulated by Ang-II which increases intracellular Ca2+[47,60]; its proliferative capacity is also enhanced as showed recently by Liu et al[61] who observed that Ang-II prompts HSC proliferation and DNA synthesis and also facilitates its contraction and collagen synthesis. These properties of HSCs are expressed through the mitogen-activated protein kinases (MAPK), a family of ubiquitous proline-directed, protein-serine/threonine kinases, which participate in signal transduction pathways that control intracellular events including apoptosis, cell growth, prostanoid formation, and other cellular dysfunctions when induced by oxidants or pro-inflammatory cytokines. These events are reversed by AT1 receptor blockade. By acting on the AT1 receptors in activated HSCs, Ang-II also stimulates, via PKC intracellular signalling cascade, TIMP-1. This effect inhibits the activity of MMP which are responsible for collagen degradation and thus facilitates the progression of hepatic fibrosis[62].

Almost all the functions of HSCs, including the induction of proinflammatory cytokines, expression of NF-κB and production of ECM, are largely mediated by ROS generated by a nonphagocytic form of NADPH oxidase, which also plays a role in the inflammatory actions of Kupffer cells. NADPH oxidase is expressed at higher levels in response to cytokines and under inflammatory conditions, generating more free radicals[58], while Ang-II also can induce supplementary production of ROS, providing a potentiating mechanism and creating an autocrine loop in which liver injury increases Ang-II production that in turn perpetuates liver damage and fibrosis.

In opposition to the effects driven by the AT1 activation by Ang-II, ACE2 and its product Ang-1-7, Mas receptors may counteract the adverse effects of Ang-II in liver disease. Herath et al[63] examined the expression of these novel components of RAS and the production of Ang-1-7 in the bile duct ligated rats and observed that hepatic ACE2 gene and activity, plasma Ang-1-7 and Mas receptor expression increased after bile duct ligation. Moreover, perfusion experiments confirmed that bile-duct ligated livers produced increased Ang-1-7 from Ang-II and this was augmented by ACE inhibition, leading to the conclusion that the RAS activation in chronic liver injury is associated with upregulation of ACE2, Mas and hepatic conversion of Ang-II to Ang-1-7. These results support the theory that the presence of an ACE2-Ang-1-7-Mas axis in liver injury may moderate the effects of Ang-II. Furthermore, Mas receptor antagonists have been tested in male Wistar rats subjected to sham-surgery or bile duct ligation[64]. Plasma renin activity and RAS components, as well as liver hydroxyproline and total TGF-β1 have been assessed, showing that renin activity, Ang-I, Ang-II and Ang-1-7 were progressively increased. Changes in RAS profile correlated with histological signs of fibrosis and deterioration in liver function while pharmacological blockade of the (Ang-1-7) receptor aggravated fibrosis with a significant elevation in hydroxyproline and total TGF-β1, suggesting that Ang-1-7 plays a protective role in hepatic fibrosis.

By observing in clinical conditions significant reduction of insulin resistance by both ARBs, as well as a moderate decrease of cytolysis in patients having NASH and mild-to-moderate hypertension, our study confirms, at least in part, these existing experimental data. There is, however, some unexplained issues, for example, why only telmisartan showed significant antifibrotic effects and why only this drug was able to improve the NAS score. Of course, a reasonable explanation could be the specific PPARγ modulatory activity of this ARB, but also other unique properties of this drug can contribute to this effect. As extensively discussed elsewhere[15], it seems that various ARBs have different “second-level” pharmacologic effects, unrelated to presence or absence of certain PPAR-modulating activity, as for example candesartan, which shows capacities to decrease liver fibrosis and diminish portal pressure in Child A cirrhotic patients[65], but do not have significant PPAR-modulating activity. It is subsequently possible that the better clinical results observed for telmisartan are driven through some undisclosed mechanism(s) that further studies will undoubtedly unveil.

Nevertheless, the limitations of our study are linked to the small number of patients, lack of a complementary analysis of plasma fibrosis markers and of serum leptin and adiponectin levels, and even a more complex evaluation of the lipid profile of the patients. Additionally, despite the fact that a rigorous analysis of anti-dislipidaemic effects of the two ARBs was out of our scope, we can, however, question as others[66] did, if the lipid-lowering effects observed for telmisartan, although statistically significant, have any clinical relevance and if the cytolysis improvement noticed for both ARBs has any impact for the clinical outcome of NASH. However, as the renin-angiotensin system plays a central role in IR and subsequently in NAFLD/NASH as the hepatic expression of MS, an attempt to block the deleterious effects of its overexpression seems correct and further studies are certainly needed to confirm weather an ARB can be a first-option drug for controlling IR, cytolysis and liver fibrosis in hypertension-associated NASH.


Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive chronic liver disease leading to cirrhosis and hepatocellular carcinoma. These conditions, considered hepatic components of the metabolic syndrome (MS) are triggered by insulin resistance. To date, no therapy provided evidence of significant efficacy, and as a consequence, no approved therapeutic options are available worldwide.

Research frontiers

Although IR plays a pivotal role in NASH/NAFLD, potential therapies tested for these conditions treat only its consequences or try to eliminate excessive fat. As the renin-angiotensin system (RAS) plays a central role in IR and subsequently in NAFLD/NASH, an attempt to block the deleterious effects of its overexpression seems an attractive breakthrough. By inhibiting RAS they can achieve an improvement of intracellular insulin signalling pathway, a better control of adipose tissue proliferation and adipokine production and a more balanced production for various cytokines. At the same time, by controlling the local RAS in the liver, they might be able to prevent at least fibrosis and to slow down the vicious cycle that links steatosis to necroinflammation. By targeting pancreatic effects of angiotensin they would be able to preserve an adequate insulin secretion and acquire a better metabolic balance.

Innovations and breakthroughs

This is the first human blinded trial evaluating the effects of telmisartan and valsartan in steatohepatitis that uses paired liver biopsies with NASH score (NAS) evaluation, simultaneously with cytolysis, IR and lipid profile assessment. Although serum aminotransferases did not normalized, telmisartan can reduce cytolysis by 30.28% and can improve IR by 42.63% consequently with a significant decrease of NAS and fibrosis scores and an amelioration of the lipid profile. Conversely, despite a significant reduction of cytolysis levels by 23.22% and of IR by 21.4%, valsartan did not improved liver histology (except steatosis) and had no effect on plasma lipids.


ARBs are angiotensin receptor blockers, non-peptide compounds that have a binding affinity to the receptor AT1 of angiotensin thus inducing an irreversible or competitive blockade of the physiologic agonists.

Peer review

By observing in clinical conditions significant reduction of IR by both ARBs, as well as a moderate decrease of cytolysis, the study confirms that ARBs can act as an elegant tool for adequate correction of various imbalances that act consensually in steatohepatitis. ARBs not only can correct hypertension, but also can act on IR and the hepatic RAS, preventing and treating steatohepatitis as an end-organ effect of MS. On the other hand, ARBs can prevent collagen synthesis and further progression to cirrhosis. As equally cheap, effective and well-supported antifibrotic therapies are hard to be found we can predict that this property will put ARBs in the pole position for treating at least the liver fibrosis.


Supported by A Grant from the Romanian National Authority for Scientifical Research

1.  Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883-889.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25:143-154.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-140.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5-13.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Diehl AM. Fatty liver, hypertension, and the metabolic syndrome. Gut. 2004;53:923-924.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21:27-41.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Bjornsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2008;54:7-18.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Division of Adult and Community Health. Behavioral Risk Factor Surveillance System Online Prevalence Data. Atlanta, GA. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System. 2007;13:18.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut. 1999;45 Suppl 4:IV1-IV11.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option? Adv Ther. 2008;25:1141-1174.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Maeyama S, Saito S. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci. 2007;52:3455-3464.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2007;364:801-807.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. 2006;47:1003-1009.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Yoshida T, Yamagishi S, Matsui T, Nakamura K, Ueno T, Takeuchi M, Sata M. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res. 2008;36:237-243.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Walcher D, Hess K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension. 2008;51:259-266.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia. 2006;49:3094-3099.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension. 2006;48:51-57.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, Hartge M, Gust R, Staels B, Unger T. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes. 2008;57:1405-1413.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222-1225.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, Hasegawa T, Aoshima M, Miyokawa N. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12:322-326.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16:39-46.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med. 2007;46:1331-1336.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55:1149-1154.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Usui I, Fujisaka S, Yamazaki K, Takano A, Murakami S, Yamazaki Y, Urakaze M, Hachiya H, Takata M, Senda S. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77:210-214.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Tripp B, Ludvik B. Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study. Wien Med Wochenschr. 2007;157:223-227.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Sasaki T, Noda Y, Yasuoka Y, Irino H, Abe H, Adachi H, Hattori S, Kitada H, Morisawa D, Miyatake K. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res. 2008;31:921-929.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther. 2007;24:146-153.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Inoue T, Morooka T, Moroe K, Ikeda H, Node K. Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR). Horm Metab Res. 2007;39:372-376.  [PubMed]  [DOI]  [Cited in This Article: ]
34.  Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol. 2006;47:21-28.  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res. 2005;28:209-214.  [PubMed]  [DOI]  [Cited in This Article: ]
36.  Jordan J, Engeli S, Boschmann M, Weidinger G, Luft FC, Sharma AM, Kreuzberg U. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens. 2005;23:2313-2318.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens. 1997;6:28-34.  [PubMed]  [DOI]  [Cited in This Article: ]
38.  Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-271.  [PubMed]  [DOI]  [Cited in This Article: ]
39.  Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag. 2007;3:125-137.  [PubMed]  [DOI]  [Cited in This Article: ]
40.  Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.  [PubMed]  [DOI]  [Cited in This Article: ]
41.  Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12:70-88.  [PubMed]  [DOI]  [Cited in This Article: ]
42.  Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263.  [PubMed]  [DOI]  [Cited in This Article: ]
43.  Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab. 2007;292:E1280-E1287.  [PubMed]  [DOI]  [Cited in This Article: ]
44.  Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, Takahashi M, Akisawa N, Iwasaki S, Oben JA. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007;45:1375-1381.  [PubMed]  [DOI]  [Cited in This Article: ]
45.  Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci (Lond). 2007;113:109-118.  [PubMed]  [DOI]  [Cited in This Article: ]
46.  Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Iwai M, Horiuchi M, Chayama K. Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem Biophys Res Commun. 2006;346:658-664.  [PubMed]  [DOI]  [Cited in This Article: ]
47.  Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:G642-G651.  [PubMed]  [DOI]  [Cited in This Article: ]
48.  Toblli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring). 2008;16:770-776.  [PubMed]  [DOI]  [Cited in This Article: ]
49.  Takeshita Y, Takamura T, Ando H, Hamaguchi E, Takazakura A, Matsuzawa-Nagata N, Kaneko S. Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes. Eur J Pharmacol. 2008;579:426-432.  [PubMed]  [DOI]  [Cited in This Article: ]
50.  Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens. 2001;10:321-329.  [PubMed]  [DOI]  [Cited in This Article: ]
51.  Jamaluddin M, Meng T, Sun J, Boldogh I, Han Y, Brasier AR. Angiotensin II induces nuclear factor (NF)-kappaB1 isoforms to bind the angiotensinogen gene acute-phase response element: a stimulus-specific pathway for NF-kappaB activation. Mol Endocrinol. 2000;14:99-113.  [PubMed]  [DOI]  [Cited in This Article: ]
52.  Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest. 2004;84:153-159.  [PubMed]  [DOI]  [Cited in This Article: ]
53.  Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, Iredale JP, Forbes SJ. The bone marrow functionally contributes to liver fibrosis. Gastroenterology. 2006;130:1807-1821.  [PubMed]  [DOI]  [Cited in This Article: ]
54.  Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.  [PubMed]  [DOI]  [Cited in This Article: ]
55.  Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002;2:46-53.  [PubMed]  [DOI]  [Cited in This Article: ]
56.  Roberts AB, Russo A, Felici A, Flanders KC. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann N Y Acad Sci. 2003;995:1-10.  [PubMed]  [DOI]  [Cited in This Article: ]
57.  Gabele E, Brenner DA, Rippe RA. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci. 2003;8:d69-d77.  [PubMed]  [DOI]  [Cited in This Article: ]
58.  Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218.  [PubMed]  [DOI]  [Cited in This Article: ]
59.  Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001;34:89-100.  [PubMed]  [DOI]  [Cited in This Article: ]
60.  Baik SK, Jo HS, Suk KT, Kim JM, Lee BJ, Choi YJ, Kim HS, Lee DK, Kwon SO, Lee KI. [Inhibitory effect of angiotensin II receptor antagonist on the contraction and growth of hepatic stellate cells]. Korean J Gastroenterol. 2003;42:134-141.  [PubMed]  [DOI]  [Cited in This Article: ]
61.  Liu J, Gong H, Zhang ZT, Wang Y. Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J (Engl). 2008;121:161-165.  [PubMed]  [DOI]  [Cited in This Article: ]
62.  Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol. 2007;22 Suppl 1:S93-S95.  [PubMed]  [DOI]  [Cited in This Article: ]
63.  Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM, Angus PW. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol. 2007;47:387-395.  [PubMed]  [DOI]  [Cited in This Article: ]
64.  Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, Barcelos LS, Collares GB, Simoes e Silva AC. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol. 2007;46:674-681.  [PubMed]  [DOI]  [Cited in This Article: ]
65.  Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, Alessandria C, Bonardi R, Saracco G. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol. 2007;46:1026-1033.  [PubMed]  [DOI]  [Cited in This Article: ]
66.  Derosa G, Cicero AF, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, Fogari R. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther. 2004;26:1228-1236.  [PubMed]  [DOI]  [Cited in This Article: ]